191 results on '"Marzo, Manuela"'
Search Results
2. Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
3. Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease.
4. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
5. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
6. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
7. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
8. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
9. SICUS and CEUS imaging in Crohn’s disease: an update
10. A Case of Unrecognized Complicated Celiac Disease
11. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year
12. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study
13. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study
14. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease
15. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents
16. Ileal Crohn’s disease: CEUS determination of activity
17. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
18. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
19. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
20. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.
21. Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis.
22. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?
23. Sa1978 Infliximab Trough Levels After Dose Optimization for Loss of Response Predict Outcome at One Year
24. LONG SURVIVAL OF A PATIENT WITH IPEX SYNDROME (IMMUNODYSREGULATION, POLYENDOCRINOPATHY, ENTEROPATHY, X-LYNKED)
25. ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS
26. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?
27. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
28. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases
29. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing.
30. Management of perianal fistulas in Crohn's disease: an up-to-date review
31. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases
32. Prevention and Treatment of Venous Thromboembolism in Patients with IBD
33. Tu1313 Infliximab Is More Effective Than Azathioprine in the Long-Term Prevention of Postoperative Recurrence of Crohn's Disease
34. Tu1315 Loss of Response in IBD Patients on Infliximab Treatment: Assay of Infliximab Trough Levels and Total Antibodies to Infliximab
35. Tu1319 Paradoxical Psoriasis in a Large Cohort of IBD Patients Treated With Anti-TNF Alpha: 5 Years-Follow-Up Study
36. Management of perianal fistulas in Crohn’s disease: An up-to-date review
37. Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis
38. 342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens
39. Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis
40. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis
41. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab
42. Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission.
43. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.
44. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity
45. Treatment of Crohn’s disease with colony-stimulating factors: An overview
46. Su1205 Long-Term Outcome of Treatment With Infliximab in Patients With Steroid-Dependent Ulcerative Colitis
47. 491 Prediction of Clinical Response and Mucosal Healing At One Year by Faecal Calprotectin Assay After Induction With Anti-TNF Alpha Agents in IBD Patients
48. Infliximab in Steroid-dependent Ulcerative Colitis
49. FOXP3+T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFαAgents
50. 1127 Infliximab in Steroid-Dependent Ulcerative Colitis: Efficacy and Predictors of Clinical and Endoscopic Remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.